ArticleScientific reports2018
Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The role of variables of aquatic training performed in the upright position in improving the lipid profile of adults: systematic review with meta-analysis and meta regression.Scientific reports · 2025Pooled it
- Natriuretic Peptides as Multisystem Regulators: From Clinical Biomarkers to Therapeutic Targets in Cardio-immunology.Cardiovascular drugs and therapy · 2026Review
- A small‑molecule HDAC/PDE modulator activates human adipocyte UCP1 and resolves inflammatory signaling.Journal of translational medicine · 2026Article
- Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy.Cardiovascular diabetology · 2025Article
- Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome.Diabetology & metabolic syndrome · 2025Article
- Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.Diabetes, obesity & metabolism · 2025Article
- Targeting L-arginine/NO/cGMP/KFrontiers in pharmacology · 2025Review
- Pharmacologic Treatment of Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction: Are There More Arrows on Our Bow?Journal of clinical medicine · 2024Article
- Loss of atrial natriuretic peptide signaling causes insulin resistance, mitochondrial dysfunction, and low endurance capacity.Science advances · 2024Article
- Blunted increase in plasma BNP during acute coronary syndrome attacks in obese patients.International journal of cardiology. Heart & vasculature · 2024Article
- Article
- Aging impairs cold-induced beige adipogenesis and adipocyte metabolic reprogramming.bioRxiv : the preprint server for biology · 2024Article
- Article
- MANP in Hypertension With Metabolic Syndrome: Proof-of-Concept Study of Natriuretic Peptide-Based Therapy for Cardiometabolic Disease.JACC. Basic to translational science · 2024Article
- Novel enhancers of guanylyl cyclase-A activity acting via allosteric modulation.British journal of pharmacology · 2023Article
- Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.American journal of physiology. Heart and circulatory physiology · 2023Article
- Effects of neprilysin and neprilysin inhibitors on glucose homeostasis: Controversial points and a promising arena.Journal of diabetes · 2023Review
- Role of Cardiac Natriuretic Peptides in Heart Structure and Function.International journal of molecular sciences · 2022Review
- Exogenous ANP Treatment Ameliorates Myocardial Insulin Resistance and Protects against Ischemia-Reperfusion Injury in Diet-Induced Obesity.International journal of molecular sciences · 2022Article
- Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.Biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust associations between low plasma level of natriuretic peptides (NP) and increased risk of type 2 diabetes (T2D) have been recently reported in humans. Adipose tissue (AT) is a known target of NP. However it is unknown whether NP signalling in human AT relates to insulin sensitivity and modulates glucose metabolism. We here show in two European cohorts that the NP receptor guanylyl cyclase-A (GC-A) expression in subcutaneous AT was down-regulated as a function of obesity grade while adipose NP clearance receptor (NPRC) was up-regulated. Adipose GC-A mRNA level was down-regulated in prediabetes and T2D, and negatively correlated with HOMA-IR and fasting blood glucose. We show for the first time that NP promote glucose uptake in a dose-dependent manner. This effect is reduced in adipocytes of obese individuals. NP activate mammalian target of rapamycin complex 1/2 (mTORC1/2) and Akt signalling. These effects were totally abrogated by inhibition of cGMP-dependent protein kinase and mTORC1/2 by rapamycin. We further show that NP treatment favoured glucose oxidation and de novo lipogenesis independently of significant gene regulation. Collectively, our data support a role for NP in blood glucose control and insulin sensitivity by increasing glucose uptake in human adipocytes. This effect is partly blunted in obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.